878 related articles for article (PubMed ID: 26419263)
1. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
Rainville N; Jachimowicz E; Wojchowski DM
Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
[TBL] [Abstract][Full Text] [Related]
2. Phospho-PTM proteomic discovery of novel EPO- modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 Signaling.
Held MA; Greenfest-Allen E; Su S; Stoeckert CJ; Stokes MP; Wojchowski DM
Cell Signal; 2020 May; 69():109554. PubMed ID: 32027948
[TBL] [Abstract][Full Text] [Related]
3. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.
Tanaka T; Nangaku M
Exp Cell Res; 2012 May; 318(9):1068-73. PubMed ID: 22414872
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin mimetic peptides and erythropoietin fusion proteins for treating anemia of chronic kidney disease.
Gupta N; Wish JB
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):345-350. PubMed ID: 29746307
[TBL] [Abstract][Full Text] [Related]
5. Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?
Locatelli F; Del Vecchio L
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):339-344. PubMed ID: 29846220
[TBL] [Abstract][Full Text] [Related]
6. Guinea pig serum erythropoietin (EPO) selectively stimulates guinea pig erythroid progenitors: human or mouse erythroid progenitors do not form erythroid burst-forming unit colonies in response to guinea pig serum EPO.
Stopka T; Zivny JH; Goldwasser E; Prchal JF; Necas E; Prchal JT
Exp Hematol; 1998 Aug; 26(9):910-4. PubMed ID: 9694513
[TBL] [Abstract][Full Text] [Related]
7. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
Hedley BD; Allan AL; Xenocostas A
Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietic agents and the elderly.
Agarwal N; Prchal JT
Semin Hematol; 2008 Oct; 45(4):267-75. PubMed ID: 18809098
[TBL] [Abstract][Full Text] [Related]
9. Biological functions and therapeutic use of erythropoiesis-stimulating agents: perplexities and perspectives.
Merchionne F; Dammacco F
Br J Haematol; 2009 Jul; 146(2):127-41. PubMed ID: 19388936
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietins: a common mechanism of action.
Elliott S; Pham E; Macdougall IC
Exp Hematol; 2008 Dec; 36(12):1573-84. PubMed ID: 18922615
[TBL] [Abstract][Full Text] [Related]
11. New Treatment Approaches for the Anemia of CKD.
Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
[TBL] [Abstract][Full Text] [Related]
12. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia.
Landau D; London L; Bandach I; Segev Y
PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538
[TBL] [Abstract][Full Text] [Related]
13. Investigational therapies for renal disease-induced anemia.
Schmid H; Jelkmann W
Expert Opin Investig Drugs; 2016 Aug; 25(8):901-16. PubMed ID: 27122198
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin ameliorates early brain injury after subarachnoid haemorrhage by modulating microglia polarization via the EPOR/JAK2-STAT3 pathway.
Wei S; Luo C; Yu S; Gao J; Liu C; Wei Z; Zhang Z; Wei L; Yi B
Exp Cell Res; 2017 Dec; 361(2):342-352. PubMed ID: 29102603
[TBL] [Abstract][Full Text] [Related]
15. Dominant negative effect of a truncated erythropoietin receptor (EPOR-T) on erythropoietin-induced erythroid differentiation: possible involvement of EPOR-T in ineffective erythropoiesis of myelodysplastic syndrome.
Shimizu R; Komatsu N; Miura Y
Exp Hematol; 1999 Feb; 27(2):229-33. PubMed ID: 10029161
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors.
Brines M
Blood Purif; 2010; 29(2):86-92. PubMed ID: 20093809
[TBL] [Abstract][Full Text] [Related]
17. Renal anemia: from incurable to curable.
Sato Y; Yanagita M
Am J Physiol Renal Physiol; 2013 Nov; 305(9):F1239-48. PubMed ID: 23884144
[TBL] [Abstract][Full Text] [Related]
18. The role of erythropoietin and erythropoietin receptor in malignant laryngeal tumors.
Vukelic J; Dobrila-Dintinjana R; Jonjic N; Dekanic A; Ilijic V
Med Hypotheses; 2013 Dec; 81(6):1155-8. PubMed ID: 24134826
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin and erythropoiesis stimulating agents.
Debeljak N; Sytkowski AJ
Drug Test Anal; 2012 Nov; 4(11):805-12. PubMed ID: 22508651
[TBL] [Abstract][Full Text] [Related]
20. EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.
Reinbothe S; Larsson AM; Vaapil M; Wigerup C; Sun J; Jögi A; Neumann D; Rönnstrand L; Påhlman S
Biochem Biophys Res Commun; 2014 Feb; 445(1):163-9. PubMed ID: 24502950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
